40832-82-4

Usage

Uses

Used in Organic Synthesis:
N-[2-Nitro-4-(trifluoromethyl)phenyl]pyrrolidine is utilized as a key intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structural features, including the trifluoromethyl group and the nitro group, provide opportunities for further chemical reactions and modifications, making it a valuable component in the synthesis of specialty chemicals and pharmaceutical precursors.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, N-[2-Nitro-4-(trifluoromethyl)phenyl]pyrrolidine is employed as a research tool to explore its potential as a lead compound for drug development. Its structural attributes may offer novel binding interactions with biological targets, which could be harnessed to develop new therapeutic agents. The ongoing study of N-[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]PYRROLIDINE aims to uncover its pharmacological properties and evaluate its efficacy and safety in treating specific medical conditions.
Used in Pharmaceutical Drug Development:
N-[2-Nitro-4-(trifluoromethyl)phenyl]pyrrolidine may have potential applications in the development of pharmaceutical drugs, given its unique chemical structure and reactivity. N-[2-NITRO-4-(TRIFLUOROMETHYL)PHENYL]PYRROLIDINE could serve as a starting point for the design of new drugs targeting a range of diseases and conditions. Its potential uses in drug development are currently being explored through preclinical and clinical research to assess its therapeutic potential and optimize its pharmacological profile for clinical applications.

InChI:InChI=1/C7F8/c8-1-2(9)6(13)4(11)3(10)5(1,12)7(6,14)15

Upstream product

• 123-75-1 pyrrolidine 
• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 
• 1960-59-4 2-nitro-1-phenoxy-4-(trifluoromethyl)benzene 
• 121-17-5 2-chloro-3-nitro-5-trifluoromethylbenzene 

Downstream Products

• 133184-80-2 2-(pyrrolidin-1-yl)-5-(trifluoromethyl)aniline 

Relevant academic research and scientific papers

Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity

Malaria is a devastating parasitic disease caused by parasites from the genus Plasmodium. Therapeutic resistance has been reported against all clinically available antimalarials, threatening our ability to control the disease and therefore there is an ongoing need for the development of novel antimalarials. Towards this goal, we identified the 2-(N-phenyl carboxamide) triazolopyrimidine class from a high throughput screen of the Janssen Jumpstarter library against the asexual stages of the P. falciparum parasite. Here we describe the structure activity relationship of the identified class and the optimisation of asexual stage activity while maintaining selectivity against the human HepG2 cell line. The most potent analogues from this study were shown to exhibit equipotent activity against P. falciparum multidrug resistant strains and P. knowlesi asexual parasites. Asexual stage phenotyping studies determined the triazolopyrimidine class arrests parasites at the trophozoite stage, but it is likely these parasites are still metabolically active until the second asexual cycle, and thus have a moderate to slow onset of action. Non-NADPH dependent degradation of the central carboxamide and low aqueous solubility was observed in in vitro ADME profiling. A significant challenge remains to correct these liabilities for further advancement of the 2-(N-phenyl carboxamide) triazolopyrimidine scaffold as a potential moderate to slow acting partner in a curative or prophylactic antimalarial treatment.

Access to Polycyclic Indole-3,4-Fused Nine-Membered Ring via Cascade 1,6-Hydride Transfer/Cyclization

A cascade aldimine condensation/1,6-hydride transfer/Mannich-type cyclization of indole-derived phenylenediamine with aldehydes was developed for one-step construction of a polycyclic indole-3,4-fused skeleton. Aldehyde serves as a key to start the whole process, including 1,6-hydride transfer enabled δ-C(sp3)-H activation of the secondary amine. The challenges of construction of medium-sized rings are addressed via hydride transfer chemistry.

Tert-amino effect-promoted rearrangement of aryl isothiocyanate: A versatile approach to benzimidazothiazepines and benzimidazothioethers

A general and practical approach to benzimidazothiazepine and benzimidazothioether derivatives via an intramolecular nucleophilic addition/ring expansion rearrangement of aryl isothiocyanates promoted by the tert-amino effect has been developed. This reaction is catalyzed by low-cost camphorsulfonic acid and tolerates a broad substrate scope with complete atom economy. Structurally intriguing benzimidazothiazepine and benzimidazothioether products could be easily obtained by a simple operation in good to excellent yield (up to 98%).

Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs)

The serine/arginine-rich protein kinases (SRPKs) have frequently been found with altered activity in a number of cancers, suggesting they could serve as potential therapeutic targets in oncology. Here we describe the synthesis of a series of twenty-two tr

The effects of ring substituents and leaving groups on the kinetics of SNAr reactions of 1-halogeno- and 1-phenoxy-nitrobenzenes with aliphatic amines in acetonitrile

Rate constants are reported for the reactions of a series of 1-chloro-, 1-fluoro- and 1-phenoxy-nitrobenzenes activated by CF3 or CN groups or by ring-nitrogen with n-butylamine, pyrrolidine or piperidine in acetonitrile. The results are compar

METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT

The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhi